Condition Results Operations The following commentary read conjunction consolidated financial statements accompanying notes EXECUTIVE OVERVIEW Description Company Business Segments Baxter International Inc subsidiaries provides broad portfolio essential healthcare products across portfolio including acute chronic dialysis therapies sterile IV solutions infusion systems devices parenteral nutrition therapies inhaled anesthetics generic injectable pharmaceuticals surgical hemostat sealant products The company global footprint critical nature products services play key role expanding access healthcare emerging developed countries These products used hospitals kidney dialysis centers nursing homes rehabilitation centers doctors offices patients home physician supervision Separation Baxalta Incorporated On July 1 2015 Baxter completed distribution approximately 80.5 outstanding common stock biopharmaceuticals business Baxalta Incorporated Baxalta Baxter stockholders Distribution As result separation operating results Baxalta reflected discontinued operations years ended December 31 2017 2016 2015 Refer Note 2 Item 8 additional information regarding separation Baxalta Unless otherwise stated financial results herein reflect continuing operations Acquisition Claris Injectables Limited On July 27 2017 Baxter acquired 100 percent Claris Injectables Limited Claris wholly owned subsidiary Claris Lifesciences Limited total cash consideration approximately 629 million net cash acquired Through acquisition Baxter added capabilities production essential generic injectable medicines anesthesia analgesics renal anti-infectives critical care variety presentations including bags vials ampoules Refer Note 5 Item 8 additional information regarding acquisition Claris Pending Acquisition Recothrom Preveleak In January 2018 Baxter agreed acquire two hemostat sealant products Mallinckrodt plc RECOTHROM Thrombin topical Recombinant first stand-alone recombinant thrombin PREVELEAK Surgical Sealant used vascular reconstruction The purchase price includes upfront payment approximately 153 million potential contingent payments future The transaction expected close first half 2018 subject satisfaction regulatory approvals closing conditions Total sales products approximated 56 million twelve months ended September 29 2017 Segments In 2017 Baxter announced change commercial structure improve performance optimize costs increase speed decision-making process drive improved accountability across company As result company reports financial performance based new segments Americas North South America EMEA Europe Middle East Africa APAC Asia-Pacific For financial information Baxter segments see Note 17 Item 8 Annual Report Form 10-K Baxter approximately 47,000 employees conducted business 100 countries December 31 2017 In 2017 company generated approximately 60 revenues outside United States The company maintained approximately 50 manufacturing facilities 100 distribution facilities United States Europe Asia-Pacific Latin America Canada December 31 2017 Financial Results Baxter global net sales totaled 10.6 billion 2017 increase 4 2016 reported constant currency basis International sales totaled 6.1 billion 2017 increase 2 compared 2016 reported constant currency basis Sales United States totaled 4.5 billion 2017 increase 6 compared 2016 20 Baxter income continuing operations 2017 totaled 724 million 1.30 per diluted share compared 4,966 million 9.01 per diluted share prior year Income continuing operations 2017 included special items resulted net decrease income continuing operations 652 million 1.18 per diluted share Income continuing operations 2016 included special items resulted net increase income continuing operations 3.9 billion 7.05 per diluted share The company special items discussed Results Operations section Baxter financial results included R&D expenses totaling 617 million 2017 reflects company focus balancing increased investments support company new product pipeline efforts optimize overall R&D spending continuous evaluation portfolio The company financial position remains strong operating cash flows continuing operations totaling 1.9 billion 2017 The company continued execute disciplined capital allocation framework designed optimize stockholder value creation reinvestment businesses dividends share repurchases well acquisitions business development initiatives discussed Strategic Objectives section Capital investments totaled 634 million 2017 company continues invest across businesses support future growth including additional investments support new existing product capacity expansions The company investments capital expenditures 2017 focused projects improve production efficiency enhance manufacturing capabilities support strategy geographic expansion select investments growing markets The company also continued return value stockholders form dividends During 2017 company paid cash dividends shareholders totaling 315 million Additionally 2017 company repurchased 9.2 million shares cash repurchases pursuant Rule 10b5-1 repurchase plans otherwise Strategic Objectives Baxter continues focus several key objectives successfully execute long-term strategy achieve sustainable growth deliver enhanced stockholder value Baxter diversified broad portfolio medical products treat life-threatening acute chronic conditions global presence core components company strategy achieve objectives The company focused three strategic factors part pursuit industry leading performance optimizing core portfolio globally operational excellence focused streamlining cost structure enhancing operational efficiency following disciplined balanced approach capital allocation Optimizing Core Portfolio Globally Baxter categorized product portfolio four strategic business groupings Those groupings include core growth core return capital maintain manage differently strategic bets Within core growth grouping Baxter looks invest long-term higher margin growth Baxter looks optimize return investment maintain enhance market position core return capital products Maintain manage differently products Baxter looks sustain reposition underlying investment Finally strategic bet grouping includes products Baxter evaluating market position investment strategy These products cover mature emerging markets Baxter continues evaluate product category placement light shifting market dynamics company priorities may reassign product category different business grouping time time As part portfolio review Baxter seeks optimize position product areas company stable profitable business model identify alter investments products reached end life cycles respect market positions evolved unfavorably In course Baxter expects continue reallocate capital promising opportunities business groupings described As part strategy Baxter shifting investments drive innovation compelling opportunities serve patients healthcare professionals advancing business accelerate pace bringing advances market Baxter midst launching 200 new products geographic expansions line extensions 2020 including areas chronic acute renal care smart pump technology hospital pharmaceuticals nutritionals surgical sealants These comprise mix entirely new offerings marked improvements existing technologies expansion current products new geographies 21 Operational Excellence As part pursuit improved margin performance Baxter working optimize cost structure critically assessing optimal support levels light company ongoing portfolio optimization efforts The company intends continue actively manage cost structure help ensure committing resources highest value uses Such high value activities include supporting innovation building portfolio expanding patient access accelerating growth company stockholders Baxter undertaken comprehensive review aspects operations already begun implement changes line business goals Maintaining Disciplined Balanced Capital Allocation Baxter capital allocation strategies include following reinvest business funding opportunities positioned deliver sustainable growth support company innovation efforts improve margin performance return capital stockholders stock dividends meaningfully increase earnings growth share repurchases identify pursue accretive M&A opportunities generate returns targeted thresholds Responsible Corporate Citizen The company strives continued growth profitability furthering focus acting responsible corporate citizen At Baxter sustainability means creating lasting social environmental economic value addressing needs company wide-ranging stakeholder base Baxter comprehensive sustainability program focused areas company uniquely positioned make positive impact Priorities include providing employees safe healthy inclusive workplace fostering culture drives integrity strengthening access healthcare enhancing math science education driving environmental performance across product life cycle including development manufacturing transport Baxter Baxter International Foundation provide financial support product donations support critical needs assisting underserved communities providing emergency relief countries experiencing natural disasters Throughout 2017 company continued implement range water conservation strategies facility-based energy saving initiatives In area product stewardship life cycle management Baxter pursuing efforts sustainable design reduced packaging Baxter also responding challenges climate change innovative greenhouse gas emissions-reduction programs shifting less carbon-intensive energy sources manufacturing transport Additionally company developed new long-term goals drive continued environmental stewardship creating healthier sustainable communities Baxter employees work live Risk Factors The company ability sustain long-term growth successfully execute strategies discussed depends part company ability manage within increasingly competitive regulated environment address risk factors described Item 1A Annual Report Form 10-K 22 RESULTS OF OPERATIONS Special Items The following table provides summary company special items related impact line item company results continuing operations 2017 2016 2015 years ended December 31 millions 2017 2016 2015 Gross Margin Intangible asset amortization expense 154 163 158 Business optimization items1 53 156 38 Intangible asset impairment2 51 Separation-related costs3 1 1 Product-related items4 17 18 28 Claris acquisition integration expenses 8 Hurricane Maria costs 32 Total Special Items 265 353 168 Impact Gross Margin Ratio 2.6 pts 3.5 pts 1.7 pts Marketing Administrative Expenses Business optimization items1 116 173 152 Separation-related costs3 18 53 110 Claris acquisition integration expenses 20 Historical reserve adjustments 12 Litigation contractual disputes 21 Total Special Items 163 226 262 Impact Marketing Administrative Expense Ratio 1.5 pts 2.3 pts 2.6 pts Research Development Expenses Business optimization items1 80 13 Separation-related costs3 1 Total Special Items 80 14 Other Income Net Business optimization items1 3 Net realized gains Retained Shares transactions 4,391 Loss debt extinguishment 149 130 Reserve items adjustments 52 Business development items 20 Tax matter 9 Venezuela deconsolidation 33 Total Special Items 33 4,233 55 Income Tax Expense Impact special items 191 314 137 Total Special Items 191 314 137 Impact Effective Tax Rate 22.5 pts 22.1 pts 10.4 pts Intangible asset amortization expense identified special item facilitate evaluation current past operating performance similar management internally assesses performance Additional special items identified highly variable difficult predict size may substantially impact company reported operations period Management believes providing separate impact items company results accordance generally accepted accounting principles GAAP United States may provide complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another This information considered addition substitute information prepared accordance GAAP 23 1 In 2017 2016 2015 company results impacted costs associated company execution certain strategies optimize organization cost structure global basis These actions included streamlining company international operations rationalizing manufacturing facilities reducing general administrative infrastructure re-aligning certain R&D activities cancelling certain R&D programs The company recorded net business optimization charges 169 million 409 million 203 million 2017 2016 2015 respectively The company results 2017 included net charge 70 million related restructuring activities 89 million costs implement business optimization programs primarily included external consulting project employee costs 10 million accelerated depreciation associated facilities closed The 70 million restructuring charges included net 59 million employee termination costs 6 million asset impairment charges related facility closure costs 5 million exit costs The company results 2016 included net charge 285 million related restructuring activities 65 million costs implement business optimization programs primarily included external consulting project employee costs 33 million accelerated depreciation associated facilities closed 26 million Gambro integration costs The 285 million restructuring charges included net 180 million employee termination costs 54 million costs related discontinuance VIVIA home hemodialysis development program 47 million asset impairment charges related acquired in-process R&D facility closure costs 4 million exit costs The company results 2015 included net charge 130 million related restructuring activities 73 million Gambro integration costs The 130 million net restructuring charges included net 83 million employee termination costs 20 million intangible asset impairment 27 million asset impairments exit costs Refer Note 7 Item 8 information regarding charges related reserves 2 The company results 2016 included 51 million asset impairment primarily related developed technology 3 The company results 2017 2016 2015 included costs related Baxalta separation 19 million 54 million 111 million respectively 4 The company results 2017 included net charge 17 million related SIGMA SPECTRUM infusion pump inspection remediation activities historical product reserves The company results 2016 2015 included net benefit 18 million 28 million respectively primarily related adjustments COLLEAGUE SIGMA SPECTRUM infusion pump reserves Refer Note 7 Item 8 information regarding charges related reserves 5 The company results 2016 included net realized gains 4.4 billion related debt-for-equity exchanges company retained shares Baxalta certain indebtedness exchange retained shares Baxalta Baxter shares contribution retained shares Baxalta Baxter U.S pension fund 6 The company results 2016 included net debt extinguishment loss totaling 149 million related March 2016 debt-for-equity exchange certain company indebtedness certain debt redemptions The company results 2015 included loss 130 million related July 2015 tender offer certain outstanding indebtedness Refer Note 8 Item 8 additional information 7 The company results 2015 included income 52 million related litigation settlement Baxter beneficiary 8 The company results 2015 included benefit 20 million relating reversal contingent consideration milestone liabilities Refer Note 5 Item 8 information regarding company acquisitions arrangements 9 Reflected item tax impact special items identified table well net tax charge 322 million related estimated impact tax reform company tax related assets liabilities The company results 2016 included net after-tax benefit 10 million related settlement income tax matter company non-wholly owned joint venture Turkey This amount comprised 19 million included income tax expense offset 9 million non-controlling interest recorded income net 10 The company results 2017 include acquisition integration costs 28 million related company acquisition Claris 11 The company results 2017 included charge 32 million related impact Hurricane Maria company operations Puerto Rico The costs primarily include inventory fixed asset impairments well idle facility costs 12 The company's results 2017 included benefit 12 million related adjustment company's historical rebates discounts reserve 13 The company results 2017 included charge 33 million related deconsolidation Venezuelan operations 24 14 The company results 2017 included charges 21 million related litigation contractual disputes businesses arrangements company longer engaged party thereto Net Sales Percent change At actual currency rates At constant currency rates years ended December 31 millions 2017 2016 2015 2017 2016 2017 2016 United States 4,510 4,259 4,001 6 6 6 6 International 6,051 5,904 5,967 2 1 2 3 Total net sales 10,561 10,163 9,968 4 2 4 4 Net sales year ended December 31 2017 increased 4 actual constant currency rates Net sales year ended December 31 2016 increased 2 actual currency rates 4 constant currency basis Changes foreign currency exchange rates net impact net sales 2017 compared prior year Foreign currency exchange rates unfavorably impacted net sales two percentage points 2016 compared 2015 principally due strengthening U.S dollar relative British Pound Mexican Peso Colombian Peso Chinese Yuan well currencies partially offset weakening U.S dollar relative Japanese Yen The comparisons presented constant currency rates reflect comparative local currency sales prior year foreign exchange rates This measure provides information change net sales assuming foreign currency exchange rates changed prior current period The company believes non-GAAP measure change net sales constant currency rates used conjunction GAAP measure change net sales actual currency rates may provide complete understanding company operations facilitate fuller analysis company results operations particularly evaluating performance one period another During 2016 company made strategic decision exit select products certain markets including Venezuela India Turkey Overall items negative impact company net sales growth rate one percentage point 2017 In addition impact generic competition U.S cyclophosphamide negative impact net sales 25 million 2017 compared 2016 The company expects net sales U.S cyclophosphamide decrease approximately 90 million 2018 due entrance additional competitors On July 27 2017 company completed acquisition Claris wholly owned subsidiary Claris Lifesciences Limited total cash consideration 629 million net cash acquired In 2017 consolidated results include 57 million net sales related Claris acquisition In September 2017 company three Puerto Rico manufacturing facilities sustained minimal structural damage impact Hurricane Maria Notwithstanding intermittent continuing challenges local infrastructure limited production activities resumed soon thereafter company currently back pre-hurricane production levels facilities Given disruptions company manufacturing facilities result storm company net sales fourth quarter 2017 negatively impacted approximately 70 million The company currently expects disruptions negatively impact net sales first quarter 2018 approximately 25 million Global Business Unit Net Sales Reporting The company global business units GBUs reflect reorganization company business consistent new strategic framework These groupings replace company former franchises include following Renal Care includes sales company peritoneal dialysis PD hemodialysis HD additional dialysis therapies services Acute Therapies includes sales company continual renal replacement therapies CRRT organ support therapies focused intensive care unit ICU Medication Delivery includes sales company IV therapies infusion pumps administration sets drug reconstitution devices 25 Pharmaceuticals includes sales company premixed oncology drug platforms inhaled anesthesia critical care products pharmacy compounding services Nutrition includes sales company parenteral nutrition PN therapies Advanced Surgery includes sales company biological products medical devices used surgical procedures hemostasis tissue sealing adhesion prevention Other includes sales primarily company pharmaceutical partnering business The following summary net sales GBU Percent change At actual currency rates At constant currency rates years ended December 31 millions 2017 2016 2015 2017 2016 2017 2016 Renal Care 3,480 3,421 3,401 2 1 2 4 Acute Therapies 456 429 385 6 11 6 14 Medication Delivery 2,698 2,596 2,375 4 9 4 11 Pharmaceuticals 1,883 1,722 1,801 9 4 9 2 Nutrition 882 858 857 3 0 2 2 Advanced Surgery 707 690 693 2 0 2 1 Other 455 447 456 2 2 1 2 Total Baxter 10,561 10,163 9,968 4 2 4 4 Renal Care net sales increased 2 1 2017 2016 respectively Excluding impact foreign currency net sales increased 2 4 2017 2016 respectively The increase 2017 driven continued growth PD patients adoption company new Automated Peritoneal Dialysis Cyclers APD AMIA U.S HomeChoice CLARIA international markets partially offset lower sales HD products internationally Additionally net sales negatively impacted 2017 approximately 50 million compared 2016 due certain international strategic market exits The increase 2016 driven continued global growth patients new product launches improved pricing U.S PD business Acute Therapies net sales increased 6 11 2017 2016 respectively Excluding impact foreign currency net sales increased 6 14 respectively driven higher sales company CRRT systems treat acute kidney injuries Medication Delivery net sales increased 4 9 2017 2016 respectively Excluding impact foreign currency net sales increased 4 11 respectively The increase years driven select pricing improved volumes U.S IV solutions This increase also positively impacted increased sales company IV access administrative sets reflecting on-going pull company growing SPECTRUM infusion pump base Net sales negatively impacted 2017 approximately 35 million compared 2016 due certain international strategic market exits Additionally 2017 net sales negatively impacted approximately 45 million due impact Hurricane Maria Pharmaceuticals net sales increased 9 2017 decreased 4 2016 Excluding impact foreign currency net sales increased 9 2017 decreased 2 2016 The increase 2017 result increased sales pre-mixed injectable drugs result recent product launches one-time benefit pharmacy compounding early contract settlement improved pricing BREVIBLOC fast-acting IV beta blocker increased sales TransDerm Scop resulting temporary supply disruptions The acquisition Claris 2017 also contributed 57 million net sales The increase partially offset reduction sales U.S cyclophosphamide 210 million 2016 185 million 2017 due entry competitors market approximate 10 million reduction sales due impact Hurricane Maria Additionally net sales negatively impacted 2017 approximately 10 million compared 2016 due certain international strategic market exits The decrease 2016 result U.S Department Defense PROTOPAM orders 2015 reoccur 2016 reduction sales U.S cyclophosphamide 270 million 2015 210 million 2016 Nutrition net sales increased 3 2017 flat 2016 Excluding impact foreign currency net sales increased 2 period driven improved volumes new product launches ongoing geographic expansion company PN therapies Partially offsetting increase 2017 approximate 15 million reduction sales due impact Hurricane Maria Advanced Surgery net sales increased 2 2017 flat 2016 Excluding impact foreign currency net sales increased 2 1 2017 2016 respectively primarily driven improved volumes internationally Offsetting performance periods reduced sales non-core surgical products Actifuse Peristrips 26 Other net sales increased 2 2017 decreased 2 2016 Excluding impact foreign currency net sales increased 1 2017 decreased 2 2016 The increase 2017 result favorable volumes products manufactured Baxter behalf pharmaceutical partners including benefit increasing safety stock levels select products The decrease 2016 driven lower demand products manufactured Baxter behalf one pharmaceutical partners partner transitioned self-manufacture products previously manufactured Baxter Gross Margin Expense Ratios Change years ended December 31 percent net sales 2017 2016 2015 2017 2016 Gross margin 42.2 40.4 41.6 1.8 pts 1.2 pts Marketing administrative expenses 24.5 27.0 31.0 2.5 pts 4.0 pts Gross Margin The special items identified unfavorable impact 2.6 3.5 1.7 percentage points gross margin ratio 2017 2016 2015 respectively Refer Special Items section additional detail Excluding impact special items gross margin ratio increased 0.9 percentage points 2017 The gross margin ratio impacted select price increases favorable manufacturing performance benefit company business transformation initiatives aimed simplifying portfolio drive efficiency reduce costs partially offset impact foreign currency Excluding impact special items gross margin ratio increased 0.6 percentage points 2016 The gross margin ratio impacted positive sales mix improved pricing select areas portfolio favorable manufacturing performance offset reduced sales cyclophosphamide United States foreign exchange Marketing Administrative Expenses The special items identified unfavorable impact 1.5 2.3 2.6 percentage points marketing administrative expenses ratio 2017 2016 2015 respectively Refer Special Items section additional detail Excluding impact special items marketing administrative expense ratio decreased 1.7 percentage points 2017 due actions taken company restructure cost position focus expense management These savings partially offset decreased benefits marketing administrative expenses ratio lower transition service income agreement Baxalta services continues wind Excluding impact special items marketing administrative expense ratio decreased 3.7 percentage points 2016 impacted reduced pension expense benefits company actions taken restructure cost position continued focus expense management reduction expense transition services agreement Baxalta Pension Other Postemployment Benefit Plan Expense Expense related company pension postemployment benefit OPEB plans increased 9 million 2017 primarily due reduction expected return assets Expense related company pension postemployment benefit plans decreased 111 million 2016 primarily due change approach estimating employer service interest costs 706 million voluntary non-cash contribution U.S qualified plan using Retained Shares The company expects expenses pension postemployment benefit plans decrease 2018 result split freeze U.S pension plans announced January 2018 coupled stronger investment returns result additional contributions made 2017 better-than expected investment returns realized 2017 Refer Notes 1 13 Item 8 information regarding pension postemployment benefit plan expenses change income statement presentation expenses Business Optimization Items Beginning second half 2015 company initiated actions transform company cost structure enhance operational efficiency These efforts include restructuring organization optimizing manufacturing footprint R&D operations supply chain network employing disciplined cost management centralizing streamlining certain support functions Through December 31 2017 company incurred cumulative pre-tax costs 576 million related actions The costs consisted primarily employee termination costs implementation costs accelerated depreciation The company expects incur additional pretax costs approximately 240 million capital expenditures 50 million related initiatives end 2018 These costs primarily include employee termination costs implementation costs These actions aggregate expected provide future annual pretax savings approximately 975 million The savings actions impact cost sales marketing administrative expenses R&D expenses The company estimates actions taken December 31 27 2017 resulted approximately 730 million savings 2017 Approximately 90 percent expected annual pretax savings expected realized end 2018 remainder end 2020 In addition programs company recorded additional net business optimization charges 125 million 2016 These charges primarily include employee termination costs contract termination costs asset impairments Gambro integration costs Approximately 40 costs non-cash The company anticipate incurring additional costs related programs future The actions aggregate expected provide future annual pre-tax savings approximately 19 million The savings actions impact cost sales marketing administrative expenses R&D expenses Refer Note 7 Item 8 additional information regarding company business optimization initiatives Research Development Percent change years ended December 31 millions 2017 2016 2015 2017 2016 Research development expenses 617 647 603 5 7 percent net sales 5.8 6.4 6.0 0.6 pts 0.4 pts The special items identified unfavorable impact $80 million 14 million 2016 2015 respectively Excluding impact special items research development expenses ratio increased 2017 result company increased investment new product development geographic expansion Excluding impact special items research development expenses ratio decreased 2016 primarily due optimization infrastructure exit certain programs impact foreign currency Net Interest Expense Net interest expense 55 million 66 million 126 million 2017 2016 2015 respectively The decrease 2017 principally driven lower outstanding debt result first quarter 2016 debt-for-equity exchanges reduced coupon rates resulting third quarter 2016 second quarter 2017 debt issuances partially offset lower capitalized interest compared 2016 The decrease 2016 principally driven lower outstanding debt result first quarter 2016 debt-for-equity exchanges reduced coupon rates resulting third quarter 2016 debt issuance partially offset lower capitalized interest compared 2015 Refer Note 3 Item 8 summary components net interest expense 2017 2016 2015 Other Income Net Other income net 14 million 4,296 million 105 million 2017 2016 2015 respectively The current year results included 50 million income related foreign currency fluctuations principally relating intercompany receivables payables monetary assets denominated foreign currency partially offset 33 million loss deconsolidation company Venezuela operations 8 million losses related investment impairments The 2016 results included net realized gains 4.4 billion Retained Shares transactions dividend income 16 million Retained Shares 28 million income related foreign currency fluctuations principally relating intercompany receivables payables monetary assets denominated foreign currency These income items partially offset net debt extinguishment losses 153 million The 2015 results driven primarily 52 million income related favorable litigation settlement 38 million income sale available-for-sale securities 113 million income related foreign currency fluctuations principally relating intercompany receivables payables monetary assets denominated foreign currency partially offset 130 million loss extinguishment debt related July 2015 debt tender offer Income Taxes Effective Income Tax Rate The effective income tax rate continuing operations 40.5 2017 0.2 2016 8.2 2015 The special items identified unfavorable impact 22.5 percentage points effective income tax rate 2017 favorable impact 22.1 10.4 percentage points 2016 2015 respectively Refer Special Items section additional detail The company provision income taxes effective rate increased 2017 compared 2016 primarily due special items including recently enacted Tax Cuts Jobs Act 2017 2017 Tax Act tax-free net realized gains recognized 2016 Baxalta Retained Shares resolution uncertain tax positions related company former Turkish joint venture 2016 In addition company provision income taxes effective tax rate 2017 increased due tax benefits recognized 28 2016 partially settling IRS 2008-2013 income tax audit settling German 2008-2011 income tax audit miscellaneous transfer pricing matters including partial settlement interest expense deductions related company acquisition Gambro Partially offsetting increase effective tax rate benefit 56 million 2017 related deductions excess share-based compensation costs windfall tax benefits mix earnings lower tax jurisdictions relative higher tax jurisdictions Refer Note 15 Item 8 information related 2017 Tax Act The company provision income taxes effective tax rate 2016 decreased compared 2015 primarily due special items 2016 including tax-free net realized gains recognized Baxalta Retained Shares resolution uncertain tax positions related company former Turkish joint venture In addition company provision income taxes effective tax rate decreased 2016 compared 2015 due tax benefits recognized 2016 partially settling IRS 2008-2013 income tax audit settling German 2008-2011 income tax audit miscellaneous transfer pricing matters including partial settlement interest expense deductions related company acquisition Gambro mix earnings lower tax jurisdictions relative higher tax jurisdictions Also 2016 effective tax rate decreased 2015 due charges recognized 2015 related contingent tax matters primarily related transfer pricing separation Baxalta well need record valuation allowances loss-making entities Partially offsetting decrease benefits recognized 2015 reaching settlement Puerto Rico excise tax matter well U.S R&D credit resulting retroactive reinstatement December 2015 Protecting Americans Tax Hikes Act 2015 The company anticipates effective income tax rate continuing operations calculated accordance GAAP approximately 19.5 2018 This rate may impacted number factors including discrete items tax windfalls deficiencies attributable stock compensation exercises well additional audit developments tax effect special items The company future effective tax rate affected 2017 Tax Act Effective 2018 Tax Act reduces U.S statutory tax rate 35 21 creates new taxes certain foreign-sourced earnings certain related-party payments referred global intangible low-taxed income tax GILTI base erosion anti-abuse tax BEAT respectively The company currently evaluating whether subject either taxes continue review guidance released The company future effective tax rate could adversely affected earnings lower anticipated countries lower statutory rates higher anticipated countries higher statutory rates changes valuation company deferred tax assets liabilities changes tax laws regulations accounting principles well certain discrete items In addition charge recognized 2017 related 2017 Tax Act provisional changes recognized one-year measurement period may impact 2018 effective tax rate Income Continuing Operations Earnings per Diluted Share Income continuing operations 724 million 2017 5.0 billion 2016 393 million 2015 Income continuing operations per diluted share 1.30 2017 9.01 2016 0.72 2015 The significant factors events causing net changes 2016 2017 2015 2016 discussed Additionally income continuing operations per diluted share positively impacted repurchase 17.8 million shares cash repurchases equity-for-equity exchange Retained Shares outstanding Baxter shares 2016 repurchase 9.2 million shares 2017 Rule 10b5-1 purchase plans otherwise Refer Note 12 Item 8 information regarding company stock repurchases Loss Income Discontinued Operations The following table summary operating results Baxalta reflected discontinued operations years ended December 31 2017 2016 2015 Years ended December 31 millions 2017 2016 2015 Net sales 7 148 2,895 Loss income discontinued operations income taxes 1 10 752 Gain disposal discontinued operations 2 19 Income tax expense 10 177 Total loss income discontinued operations 3 1 575 Refer Note 2 Item 8 additional information regarding separation Baxalta In addition company recognized additional expense 10 million net tax 2017 related environmental clean-up costs former location Refer Note 16 Item 8 additional information regarding environmental liabilities 29 Segment results The company uses operating income segment basis make resource allocation decisions assess ongoing performance company segments Refer Note 17 Item 8 additional details regarding company segments The following summary significant factors impacting reportable segments financial results Net sales Operating income years ended December 31 millions 2017 2016 2015 2017 2016 2015 Americas 5,720 5,437 5,222 2,227 2,070 1,816 EMEA 2,731 2,697 2,774 564 476 342 APAC 2,110 2,029 1,972 512 464 405 Corporate 2,045 2,286 2,114 Total 10,561 10,163 9,968 1,258 724 449 Americas Segment operating income 2,227 million 2,070 million 1,816 million 2017 2016 2015 respectively The increase 2017 primarily driven increased sales gross margin largely due strength Medication Delivery Renal Care Pharmaceuticals GBUs In addition marketing administrative expenses lower cost savings realized company business optimization programs continued focus expense management Operating income improved 2016 due strong performance Medication Delivery Renal Care GBUs partially offset weaker performance Pharmaceuticals GBU Performance Pharmaceuticals GBU impacted reduced sales U.S cyclophosphamide U.S Department Defense PROTOPAM order 2015 reoccur 2016 EMEA Segment operating income 564 million 476 million 342 million 2017 2016 2015 respectively The increase 2017 largely driven lower marketing administrative expenses cost savings realized company business optimization programs continued focus expense management Improved performance 2016 compared 2015 largely result lower marketing administrative expenses company business optimization programs continued focus expense management These savings partially offset reduced sales margin within Renal Care GBU resulting decision forgo certain lower margin sales opportunities increased austerity measures Western Europe competitive pressures dialyzers APAC Segment operating income 512 million 464 million 405 million 2017 2016 2015 respectively The increase 2017 largely driven strong performance Renal Care Acute Therapies GBUs along lower marketing administrative expenses cost savings realized company business optimization programs continued focus expense management Improved performance 2016 result stronger sales Pharmaceuticals GBU result new contracts lower marketing administrative expenses company business optimization programs continued focus expense management Corporate Certain income expense amounts allocated segment These amounts primarily include corporate headquarters costs certain R&D costs certain GBU support costs stock compensation expense non-strategic investments related income expense certain employee benefit plan costs well certain gains losses charges business optimization asset impairments 30 LIQUIDITY AND CAPITAL RESOURCES The company cash flows reflect continuing discontinued operations Cash Flows Operations Continuing Operations Operating cash flows continuing operations totaled 1.9 billion 2017 1.6 billion 2016 1.3 billion 2015 The increases driven factors described Net Income Net income adjusted certain non-cash items depreciation amortization net periodic pension benefit OPEB costs stock compensation deferred income taxes items increased 2017 compared 2016 well 2016 compared 2015 Additionally non-cash items 2016 included net realized gains 4.4 billion related debt-for-equity exchanges Baxalta Retained Shares certain company indebtedness equity-for-equity exchange Accounts Receivable Cash flows relating accounts receivable increased 2017 2016 days sales outstanding decreased period Days sales outstanding 53.0 days 54.5 days 56.2 days 2017 2016 2015 respectively Days sales outstanding decreased 2017 2016 primarily driven timing collections certain international markets Inventories Cash flows relating inventory decreased inflow 80 million 2016 inflow 76 million 2017 The following summary inventories December 31 2017 2016 well inventory turns 2017 2016 2015 Inventory turns year calculated annualized fourth quarter cost sales divided year-end inventory balance Inventories Inventory turns millions except inventory turn data 2017 2016 2017 2016 2015 Total company 1,475 1,430 4.2 4.1 3.6 Other The changes accounts payable accrued liabilities inflow 84 million 2017 outflow 197 million 2016 236 million inflow 2015 The changes primarily driven increase tax payments 2016 primarily due tax settlement well timing payments suppliers Refer Note 15 Item 8 additional details regarding tax settlement Payments related execution company business optimization initiatives 143 million 2017 164 million 2016 89 million 2015 Refer Note 7 Item 8 information regarding business optimization initiatives Other balance sheet items net cash outflows 229 million 2017 net inflow 90 million 2016 net outflow 364 million 2015 respectively In 2016 company received U.S federal income tax refund 250 million Additionally cash contributions company pension plans totaled 242 million 66 million 157 million 2017 2016 2015 respectively Additional changes 2015 primarily driven prepaid expenses hedging activity Cash Flows Investing Activities Continuing Operations Capital Expenditures Capital expenditures relating continuing operations totaled 634 million 2017 719 million 2016 911 million 2015 The company capital expenditures consisted targeted investments projects support production PD IV solutions well expansion activities dialyzers The decline capital expenditures three years due reduction spending related ongoing projects completion certain expansion activities Acquisitions Investments Net cash outflows related acquisitions investments 686 million 2017 48 million 2016 34 million 2015 The cash outflows 2017 driven acquisition Claris rights certain molecules Celerity The cash outflows 2016 driven primarily acquisition rights vancomycin Celerity The cash outflows 2015 driven acquisition rights cefazolin injection GALAXY Container 2g/100mL Celerity 31 Refer Note 5 Item 8 information company significant acquisitions arrangements Divestitures Other Investing Activities Net cash inflows relating divestitures investing activities 10 million 2017 37 million 2016 84 million 2015 The net inflow 2017 driven proceeds received asset sales partially offset impact deconsolidation company Venezuelan operations The decrease 2015 2016 primarily driven sale certain investments assets 2015 Cash Flows Financing Activities Debt Issuances Net Payments Obligations Net cash inflows related debt financing obligations totaled 632 million 2017 primarily related issuance 600 million senior notes fixed coupon rate 1.30 due May 2025 Refer Note 8 Item 8 additional details regarding debt transactions 2017 Net cash inflows related debt financing obligations totaled 56 million 2016 primarily related 190 million repayment company 0.95 senior unsecured notes matured June 2016 130 million repayment company 5.9 senior unsecured notes matured September 2016 redemption approximately 1 billion aggregate principal amount senior notes September 2016 well repayment short-term obligations The company also 300 million net repayments related commercial paper program These cash outflows partially offset issuances debt totaling 1.6 billion senior notes August 2016 Refer Note 8 Item 8 additional details regarding debt transactions 2016 Net cash outflows related debt financing obligations totaled 2.4 billion 2015 driven approximately 6.9 billion issuances debt primarily related Baxalta senior notes borrowings company revolving credit facilities The company purchased aggregate approximately 2.7 billion principal amount notes 2015 Additionally company repaid 600 million 4.625 senior unsecured notes matured March 2015 borrowings company Euro-denominated revolving credit facility The company issued redeemed commercial paper throughout year 300 million outstanding December 31 2015 The company debt instruments discussed unsecured contain certain covenants including restrictions relating company issuance secured debt Other Financing Activities In connection separation Baxter transferred 2.1 billion cash Baxalta 2015 Cash dividend payments totaled 315 million 2017 268 million 2016 910 million 2015 The decrease cash dividend payments 2017 2016 primarily due decrease quarterly dividend separation Baxalta 2015 0.52 per share quarterly dividends beginning May 2014 0.115 per share quarterly dividends beginning July 2015 The Baxter cash dividend increased 0.13 per share quarterly dividends beginning May 2016 0.16 per share quarterly dividends May 2017 Proceeds stock issued employee benefit plans totaled 347 million 286 million 193 million 2017 2016 2015 respectively Total realized excess tax benefits 39 million 2016 7 million 2015 presented consolidated statements cash flows inflow financing section Total realized excess tax benefits 56 million 2017 presented inflow operating activities required new accounting guidance implemented 2017 Refer Note 2 Item 8 additional information regarding change accounting In 2016 company executed equity-for-equity exchange Retained Shares 11.5 million outstanding Baxter shares As authorized Board Directors company repurchases stock depending company cash flows net debt level market conditions In July 2012 Board Directors authorized repurchase 2.0 billion company common stock The Board Directors increased authority additional 1.5 billion November 2016 The company paid 287 million cash repurchase approximately 6.3 million shares pursuant authority 2016 In 2017 company paid 564 million repurchase approximately 9.2 million shares authority pursuant Rule 10b5-1 plans otherwise 1.1 billion remaining available authorization December 31 2017 The Board Directors increased authority 32 additional 1.5 billion February 2018 After giving effect February 2018 approval 2018 share repurchases 2.3 billion repurchase authority remained available February 20 2018 Credit Facilities Access Capital Credit Ratings Credit Facilities As December 31 2017 company U.S dollar-denominated senior revolving credit facility Euro-denominated senior revolving credit facility maximum capacity 1.5 billion approximately 200 million respectively maturing 2020 As December 31 2017 company compliance financial covenants agreements The non-performance financial institution supporting either credit facilities would reduce maximum capacity facilities institution respective commitment The company may option seek increase aggregate commitment U.S facility additional 750 million The facilities enable company borrow funds unsecured basis variable interest rates contain various covenants including maximum net leverage ratio maximum interest coverage ratio The company also maintains credit arrangements described Note 8 Item 8 Access Capital The company intends fund short-term long-term obligations mature cash hand future cash flows operations issuing additional debt The company 3.4 billion cash equivalents December 31 2017 adequate cash available meet operating requirements jurisdiction company operates The company invests excess cash certificates deposit money market funds diversifies concentration cash among different financial institutions The company ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company products solvency customers suppliers deterioration company key financial ratios credit ratings significantly unfavorable changes conditions However company believes sufficient financial flexibility issue debt enter financing arrangements attract long-term capital acceptable terms support company growth objectives The company continues business foreign governments certain countries including Greece Spain Portugal Italy experienced deterioration credit economic conditions As December 31 2017 company net accounts receivable public sector Greece Spain Portugal Italy totaled 149 million While economic conditions significantly impacted company ability collect receivables global economic conditions liquidity issues certain countries resulted may continue result delays collection receivables credit losses Credit Ratings The company credit ratings December 31 2017 follows Standard Poor Fitch Moody Ratings Senior debt A BBB Baa2 Short-term debt A2 F2 P2 Outlook Stable Stable Stable 33 Contractual Obligations As December 31 2017 company contractual obligations excluding accounts payable accrued liabilities payable maturing following periods millions Total Less one year One three years Three five years More five years Long-term debt capital lease obligations including current maturities 3,531 3 304 612 2,612 Interest short long-term debt capital lease obligations 1 1,522 99 195 180 1,048 Operating leases 698 129 191 132 246 Other long-term liabilities2 611 118 39 454 Purchase obligations3 571 358 184 20 9 Contractual obligations4 6,933 589 992 983 4,369 1 Interest payments debt capital lease obligations calculated future periods using interest rates effect end 2017 Projected interest payments include related effects interest rate swap agreements Certain projected interest payments may differ future based changes floating interest rates foreign currency fluctuations factors events The projected interest payments pertain obligations agreements outstanding December 31 2017 Refer Note 8 Note 9 Item 8 discussion regarding company debt instruments related interest rate agreements outstanding December 31 2017 2 The primary components long-term liabilities company consolidated balance sheet liabilities relating pension postemployment benefit plans litigation foreign currency hedges The company projected timing future cash payments based contractual maturity dates applicable estimates timing payments liabilities contractual maturity dates The actual timing payments could differ estimates The company contributed 260 million 772 million 178 million defined benefit pension OPEB plans 2017 2016 2015 respectively The timing funding future uncertain dependent future movements interest rates investment returns changes laws regulations variables Therefore table excludes pension plan cash outflows The pension plan balance included long-term liabilities excluded table totaled 952 million December 31 2017 3 Includes company significant contractual unconditional purchase obligations For cancelable agreements penalty due upon cancellation included These commitments exceed company projected requirements normal course business Examples include firm commitments raw material purchases utility agreements service contracts 4 Excludes contingent liabilities uncertain tax positions These amounts excluded contractual obligations due uncertainty regarding timing amount future payments Refer Notes 10 15 Item 8 additional information regarding commitments Off-Balance Sheet Arrangements Baxter periodically enters off-balance sheet arrangements Certain contingencies arise normal course business recorded consolidated balance sheet accordance GAAP contingent joint development commercialization arrangement payments Also upon resolution uncertainties company may incur charges excess presently established liabilities certain matters contractual indemnifications For discussion company significant off-balance sheet arrangements refer Note 10 Item 8 information regarding receivable securitizations Note 11 Item 8 regarding joint development commercialization arrangements indemnifications Note 16 Item 8 regarding legal contingencies FINANCIAL INSTRUMENT MARKET RISK The company operates global basis exposed risk earnings cash flows equity could adversely impacted fluctuations foreign exchange interest rates The company hedging policy attempts manage risks acceptable level based company judgment appropriate trade-off risk opportunity costs Refer Note 9 Note 10 Item 8 information regarding company financial instruments hedging strategies 34 Currency Risk The company primarily exposed foreign exchange risk respect revenues generated outside United States denominated Euro British Pound Chinese Yuan Korean Won Australian Dollar Canadian Dollar Japanese Yen Colombian Peso Brazilian Real Mexican Peso New Zealand Dollar The company manages foreign currency exposures consolidated basis allows company net exposures take advantage natural offsets In addition company uses derivative nonderivative financial instruments reduce net exposure foreign exchange Gains losses hedging instruments offset losses gains hedged transactions reduce earnings stockholders equity volatility relating foreign exchange Financial market currency volatility may limit company ability cost-effectively hedge exposures The company may use options forwards cross-currency swaps hedge foreign exchange risk earnings relating forecasted transactions denominated foreign currencies recognized assets liabilities The maximum term company cash flow hedge contracts place related forecasted transactions December 31 2017 12 months The company also enters derivative instruments hedge certain intercompany third-party receivables payables debt denominated foreign currencies As part risk-management program company performs sensitivity analyses assess potential changes fair value foreign exchange instruments relating hypothetical reasonably possible near-term movements foreign exchange rates A sensitivity analysis changes fair value foreign exchange option forward contracts outstanding December 31 2017 predictive nature indicated U.S Dollar uniformly weakened 10 currencies net-of-tax basis net asset balance 7 million respect contracts would decrease 25 million resulting net liability position A similar analysis performed respect option forward contracts outstanding December 31 2016 indicated net-of-tax basis net asset balance 13 million would decrease 34 million resulting net liability position The sensitivity analysis model recalculates fair value foreign exchange option forward contracts outstanding December 31 2017 replacing actual exchange rates December 31 2017 exchange rates 10 weaker compared actual exchange rates applicable currency All factors held constant These sensitivity analyses disregard possibility currency exchange rates move opposite directions gains one currency may may offset losses another currency The analyses also disregard offsetting change value underlying hedged transactions balances Interest Rate Other Risks The company also exposed risk earnings cash flows could adversely impacted fluctuations interest rates The company policy manage interest costs using mix fixed floating-rate debt company believes appropriate To manage mix cost-efficient manner company periodically enters interest rate swaps company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreed-upon notional amount The company also periodically uses forward-starting interest rate swaps treasury rate locks hedge risk earnings associated fluctuations interest rates relating anticipated issuances term debt As part risk management program company performs sensitivity analyses assess potential gains losses earnings relating hypothetical movements interest rates A 15 basis-point increase interest rates approximately 10 company weighted-average interest rate 2017 affecting company financial instruments including debt obligations related derivatives would immaterial effect company 2017 2016 2015 earnings fair value company fixed-rate debt end fiscal year CHANGES IN ACCOUNTING STANDARDS Refer Note 1 Item 8 information changes accounting standards CRITICAL ACCOUNTING POLICIES The preparation financial statements accordance GAAP requires company make estimates judgments affect reported amounts assets liabilities revenues expenses A summary company significant accounting policies included Note 1 Item 8 Certain company accounting policies considered critical policies important depiction company financial statements require significant difficult complex judgments company often requiring use estimates effects matters inherently uncertain Actual results differ 35 company estimates could unfavorable effect company results operations financial position The following summary accounting policies company considers critical consolidated financial statements Revenue Recognition Related Provisions Allowances The company policy recognize revenues product sales services earned Specifically revenue recognized persuasive evidence arrangement exists delivery occurred services rendered price fixed determinable collectability reasonably assured For product sales revenue recognized title risk loss transferred customer The shipping terms majority company revenue arrangements free board FOB destination The company sometimes enters arrangements commits delivering multiple products services customers In cases total arrangement consideration allocated deliverables based relative selling prices Then allocated consideration recognized revenue accordance principles described Selling prices determined applying selling price hierarchy Selling prices determined using vendor specific objective evidence VSOE exists Otherwise selling prices determined using third party evidence TPE If neither VSOE TPE available company uses best estimate selling prices Provisions rebates chargebacks wholesalers distributors returns discounts collectively sales deductions provided time related sales recorded reflected reduction sales The sales deductions based primarily estimates amounts earned claimed sales The company periodically systematically evaluates collectability accounts receivable determines appropriate reserve doubtful accounts In determining amount reserve company considers historical credit losses past-due status receivables payment history customer-specific information relevant factors considerations The company also provides estimated costs may incurred warranty programs cost probable reasonably estimable time related revenue recognized The cost determined based actual company experience similar products well relevant information Estimates future costs company warranty programs could change based developments future The company able estimate probability amount future developments could impact reserves believes presently established reserves adequate Pension OPEB Plans The company provides pension postemployment benefits certain employees These employee benefit expenses reported line items consolidated income statement applicable employee compensation expense The valuation funded status net periodic benefit cost plans calculated using actuarial assumptions These assumptions reviewed annually revised appropriate The significant assumptions include following interest rates used discount pension OPEB plan liabilities long-term rate return pension plan assets rates increases employee compensation used estimating liabilities anticipated future healthcare trend rates used estimating OPEB plan liability assumptions involving demographic factors retirement mortality turnover used estimating liabilities Selecting assumptions involves analysis short-term long-term historical trends known economic market conditions time valuation also called measurement date The use different assumptions would result different measures funded status net cost Actual results future could differ expected results The company able estimate probability actual results differing expected results believes assumptions appropriate The company key assumptions listed Note 13 Item 8 The critical assumptions relate plans covering U.S Puerto Rico employees plans significant company consolidated financial statements Discount Rate Assumption Effective December 31 2017 measurement date company utilized discount rates 3.62 3.51 measure benefit obligations U.S Puerto Rico pension plans OPEB plan respectively The company used broad population approximately 200 Aa-rated corporate bonds December 31 2017 determine discount rate assumption All bonds 36 denominated U.S Dollars minimum amount outstanding 50 million This population bonds narrowed broader universe approximately 700 Moody Aa rated non-callable callable make-whole provisions bonds eliminating top 10th percentile bottom 40th percentile adjust pricing anomalies represent bonds Baxter would likely select actually annuitize pension OPEB plan liabilities This portfolio bonds used generate yield curve associated spot rate curve discount projected benefit payments U.S Puerto Rico plans The discount rate single level rate produces result spot rate curve For plans Canada Japan United Kingdom Eurozone company uses method essentially described U.S Puerto Rico plans For company international plans discount rate generally determined reviewing country region-specific government corporate bond interest rates To understand impact changes discount rates pension OPEB plan cost company performs sensitivity analysis Holding assumptions constant 50 basis point i.e one-half one percent increase discount rate global pre-tax pension OPEB plan cost would decrease approximately 40 million 50 basis point decrease discount rate global pre-tax pension OPEB plan cost would increase approximately 44 million Effective January 1 2016 company changed approach used calculate service interest components net periodic benefit cost Previously company calculated service interest components utilizing single weighted-average discount rate derived yield curve used measure benefit obligation The company elected alternative approach utilizes full yield curve approach estimation components applying specific spot rates along yield curve used determination benefit obligation underlying projected cash flows The company believes approach provides precise measurement service interest costs improving correlation projected benefit cash flows corresponding spot rates The company accounted change prospectively change estimate As result change service cost interest cost plans reduced 40 million 2016 compared previous method Return Plan Assets Assumption In measuring net periodic cost 2017 company used long-term expected rate return 6.50 pension plans covering U.S Puerto Rico employees This assumption decrease 6.25 2018 This assumption applicable company OPEB plan funded The company establishes long-term asset return assumption based review historical compound average asset returns company-specific relating broad market based company asset allocation well analysis current market economic information future expectations The current asset return assumption supported historical market experience company actual targeted asset allocation In calculating net pension cost expected return assets applied calculated value plan assets recognizes changes fair value plan assets systematic manner five years The difference expected return actual return plan assets component total net unrecognized gain loss subject amortization future To understand impact changes expected asset return assumption net cost company performs sensitivity analysis Holding assumptions constant 50 basis point increase decrease asset return assumption global pre-tax pension plan cost would decrease increase approximately 22 million Other Assumptions For U.S Puerto Rico plans beginning December 31 2014 measurement date company used RP 2014 combined mortality table adjusted reflect Baxter specific past experience improvements projected using generational BB-2D projection scale adjusted long term improvement 0.8 2027 For pension plans company utilized country region-specific mortality tables calculate plans benefit obligations The company periodically analyzes updates assumptions concerning demographic factors retirement mortality turnover considering historical experience well anticipated future trends The assumptions relating employee compensation increases future healthcare costs based historical experience market trends anticipated future company actions Refer Note 13 Item 8 information regarding sensitivity OPEB plan obligation total service interest cost components OPEB plan cost potential changes future healthcare trend rates 37 Legal Contingencies The company involved product liability patent commercial regulatory legal proceedings arise normal course business Refer Note 16 Item 8 information The company records liability loss considered probable amount reasonably estimated If reasonable estimate probable loss range amount within range better estimate minimum amount range accrued If loss probable probable loss cannot reasonably estimated liability recorded The company established reserves certain legal matters At December 31 2017 total legal liabilities 41 million The company loss estimates generally developed consultation outside counsel based analyses potential outcomes With respect recording insurance recoveries completing assessment accounting company legal contingencies company separately independently analyzes insurance coverage records insurance recoveries probable occurring gross amount expected collected In performing assessment company reviews available information including historical company-specific market collection experience similar claims current facts circumstances pertaining particular insurance claim financial viability applicable insurance company companies relevant information While liability company connection certain claims cannot estimated although resolution reporting period one matters could significant impact company results operations cash flows period outcome legal proceedings expected material adverse effect company consolidated financial position While company believes valid defenses matters litigation inherently uncertain excessive verdicts occur company may future incur material judgments enter material settlements claims Deferred Tax Asset Valuation Allowances Reserves Uncertain Tax Positions Tax Reform The company maintains valuation allowances unless likely portion deferred tax asset realized Changes valuation allowances included company tax provision period change In determining whether valuation allowance warranted company evaluates factors prior earnings history expected future earnings carryback carryforward periods tax strategies could potentially enhance likelihood realization deferred tax asset The realizability assessments made given balance sheet date subject change future particularly earnings subsidiary significantly higher lower expected company takes operational tax planning actions could impact future taxable earnings subsidiary In normal course business company audited federal state foreign tax authorities periodically challenged regarding amount taxes due These challenges relate timing amount deductions allocation income among various tax jurisdictions The company believes tax positions comply applicable tax law company intends defend positions In evaluating exposure associated various tax filing positions company records reserves uncertain tax positions accordance GAAP based technical support positions company past audit experience similar situations potential interest penalties related matters The company results operations effective tax rate given period could impacted upon final resolution taxing authorities company prevailed positions reserves established required pay amounts excess established reserves On December 22 2017 2017 Tax Act enacted law new legislation contains several key tax provisions affected company including one-time mandatory transition tax accumulated foreign earnings reduction U.S corporate income tax rate 21 effective January 1 2018 among others The company required recognize effect tax law changes period enactment determining transition tax remeasuring U.S deferred tax assets liabilities well reassessing net realizability deferred tax assets liabilities In December 2017 SEC staff issued Staff Accounting Bulletin No 118 Income Tax Accounting Implications Tax Cuts Jobs Act SAB 118 allows company record provisional amounts measurement period extend beyond one year enactment date Since Tax Act passed late fourth quarter 2017 ongoing guidance accounting interpretations expected next 12 months company considers accounting transition tax deferred tax re-measurements items incomplete due forthcoming guidance ongoing analysis final year-end data tax positions The company expects complete analysis within measurement period accordance SAB 118 38 Valuation Intangible Assets Including IPR&D The company acquires intangible assets records fair value Valuations generally completed business acquisitions using discounted cash flow analysis incorporating stage completion consideration market participant assumptions The significant estimates assumptions inherent discounted cash flow analysis include amount timing projected future cash flows discount rate used measure risks inherent future cash flows assessment asset life cycle competitive trends impacting asset including consideration technical legal regulatory economic factors Each factors assumptions significantly affect value intangible asset Acquired in-process R&D IPR&D value assigned acquired technology products development received regulatory approval alternative future use Acquired IPR&D included business combination capitalized indefinite-lived intangible asset Development costs incurred acquisition expensed incurred Upon receipt regulatory approval related technology product indefinite-lived intangible asset accounted finite-lived intangible asset amortized straight-line basis estimated useful life If R&D project abandoned indefinite-lived asset charged expense R&D acquired transactions business combinations expensed immediately For transactions payments made third parties regulatory approval capitalized amortized remaining useful life related asset classified intangible assets Due inherent uncertainty associated R&D projects assurance actual results differ materially underlying assumptions used prepare discounted cash flow analyses R&D project result successful commercial product Impairment Assets Goodwill indefinite-lived intangible assets subject impairment reviews annually whenever indicators impairment exist The company assesses goodwill impairment based reporting units operating segments As December 31 2017 date company annual impairment review fair value company reporting units excess carrying values As discussed Note 6 Item 8 company performed goodwill impairment test prior reallocation goodwill new reporting units based change operating segments The company performs qualitative assessment indefinite-lived intangible assets including IPR&D least annually If intangible asset determined likely impaired result assessment company completes quantitative impairment test Intangible assets definite lives long-lived assets fixed assets reviewed impairment whenever events changes circumstances indicate carrying amount asset may recoverable Refer Note 1 Item 8 information The company impairment reviews based estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use foreign currency exchange rates selection appropriate discount rate asset groupings assumptions estimates The estimates assumptions used consistent company business plans applicable market participant views company similar companies The use alternative estimates assumptions could increase decrease estimated fair values assets potentially result different impacts company results operations Actual results may differ company estimates Stock-Based Compensation Plans Stock-based compensation cost estimated grant date based fair value award cost recognized expense ratably substantive vesting period The company stock compensation costs primarily relate awards stock options restricted stock units RSUs performance share units PSUs The company uses Black-Scholes model estimating fair value stock options significant assumptions include long-term projections regarding stock price volatility employee exercise post-vesting termination pre-vesting forfeiture behaviors interest rates dividend yields The company expected volatility assumption based weighted-average historical volatility Baxter stock implied volatility traded options Baxter stock historical volatility heavily weighted The expected life assumption primarily based vesting terms stock option historical employee exercise patterns employee post-vesting termination behavior The risk-free interest rate expected life option based U.S Treasury yield curve effect time grant The dividend yield reflects historical experience well future expectations expected life option The fair value RSUs equal quoted price company common stock date grant 39 PSUs granted 2017 based either adjusted operating margin based upon Baxter stock performance relative company peer group The vesting condition PSUs based adjusted operating margin annual performance targets set beginning year tranche award three-year service period The holder adjusted operating margin PSUs entitled receive number shares common stock equal percentage ranging 0 200 adjusted operating margin PSUs granted depending actual results compared annual performance targets Such results may adjusted based assessment individual future potential Compensation cost adjusted operating margin PSUs measured based fair value awards date specific vesting terms tranche award established The fair value awards determined based quoted price company stock grant date tranche award The compensation cost adjusted operating margin PSUs adjusted reporting date reflect estimated probability achieving adjusted operating margin vesting condition The probability achieving operating margin vesting condition compensation cost adjusted reflect 200 attainment year ended December 31 2017 The vesting condition PSUs based Baxter stock performance relative company peer group fair valued using Monte Carlo model A Monte Carlo model uses stock price volatility variables estimate probability satisfying market conditions resulting fair value award Refer Note 12 Item 8 additional information CERTAIN REGULATORY MATTERS The U.S Food Drug Administration FDA commenced inspection Claris facilities Ahmedabad India July 27 2017 immediately prior closing Claris acquisition FDA completed inspection August 4 2017 time FDA issued related Form-483 Claris 483 The Claris 483 includes number observations across variety areas The company submitted timely response Claris 483 process implementing corrective preventive actions included product recalls financially immaterial company address FDA observations items identified connection integrating Claris company quality systems In January 2014 company received Warning Letter FDA primarily directed quality systems company Round Lake Illinois facility particularly facility capacity specification developer certain company medical devices This Warning Letter lifted February 2017 The company received Warning Letter December 2013 included observations related company ambulatory infuser business Irvine California previously subject agency action This Warning Letter lifted May 2017 In June 2013 company received Warning Letter FDA regarding operations processes North Cove North Carolina Jayuya Puerto Rico facilities The company attended Regulatory Meetings FDA November 2015 concerning Jayuya facility The company also requested participated Regulatory Meeting regarding facilities July 2017 The Warning Letter addresses observations related Current Good Manufacturing Practice violations two facilities In June 2010 company received Warning Letter FDA connection inspection McGaw Park Illinois facility previously supported Renal franchise The company Round Lake facility provides related capacity Renal franchise The Warning Letter pertains processes company analyzes addresses product complaints corrective preventative action reports relevant information FDA This Warning Letter lifted February 2017 On October 9 2014 company Regulatory Meeting FDA discuss Warning Letters described At meeting company agreed work closely FDA provide regular updates progress meet requirements resolve matters identified Warning Letters described Refer Item 1A Annual Report Form 10-K additional discussion regulatory matters may impact company FORWARD-LOOKING INFORMATION This annual report includes forward-looking statements Use words may would could believes estimates projects potential expects plans seeks intends evaluates pursues anticipates continues designs impacts affects forecasts target outlook initiative objective designed priorities goal negative words similar expressions intended identify forward-looking statements represent current judgment possible future events These forward-looking statements may include statements respect accounting estimates assumptions litigation-related matters including outcomes future regulatory filings company R&D pipeline strategic objectives credit exposure foreign governments potential developments respect credit ratings investment foreign earnings estimates liabilities including related uncertain tax positions contingent payments future pension plan contributions costs discount rates rates return company exposure financial market volatility foreign currency 40 interest rate risks potential tax liability associated separation company biopharmaceuticals medical products businesses including 2016 disposition company Retained Shares Baxalta impact competition future sales growth impact sales Hurricane Maria related production disruptions future U.S cyclophosphamide sales business development activities including future pipeline recent acquisitions including Claris Injectables business optimization initiatives cost saving initiatives future capital R&D expenditures future debt issuances manufacturing expansion sufficiency company facilities financial flexibility adequacy credit facilities tax provisions reserves effective tax rate statements relate historical facts These forward-looking statements based certain assumptions analyses made light company experience perception historical trends current conditions expected future developments well factors company believes appropriate circumstances While statements represent company current judgment future may hold company believes judgments reasonable statements guarantees events financial results Whether actual future results developments conform expectations predictions subject number risks uncertainties including following factors many beyond control failure achieve long-term financial improvement goals demand market acceptance risks competitive pressures related new existing products impact products quality patient safety concerns product development risks including satisfactory clinical performance ability manufacture appropriate scale general unpredictability associated product development cycle product quality patient safety issues leading product recalls withdrawals launch delays warning letters import bans sanctions seizures litigation declining sales continuity availability pricing acceptable raw materials component supply therefore continuity manufacturing distribution inability repair existing production capacity create additional production capacity timely manner occurrence manufacturing supply difficulties including result natural disaster otherwise breaches failures company information technology systems including cyber attack future actions failures act delays acting FDA European Medicines Agency regulatory body government authority including DOJ Attorney General State could delay limit suspend product development manufacturing sale result seizures recalls injunctions monetary sanctions criminal civil liabilities failures respect company quality compliance ethics programs future actions third parties including third-party payers impact healthcare reform implementation suspension repeal replacement amendment modification similar actions undertaken United States foreign governments including respect third-party payers pricing reimbursement taxation rebate policies legislation regulation governmental pressures United States globally may affect pricing reimbursement taxation rebate policies government agencies private payers elements company business impact competitive products pricing including generic competition drug reimportation disruptive technologies global regulatory trade tax policies company ability identify business development growth opportunities successfully execute business development strategies company ability finance develop new products enhancements commercially acceptable terms ability protect enforce company owned in-licensed patent proprietary rights including trademarks copyrights trade secrets know-how patents third parties preventing restricting company manufacture sale use affected products technology impact goodwill impairments operating results 41 impact future tax liability respect separation distribution including respect Baxter Transactions including company prior disposition Retained Shares failure Baxalta Shire satisfy obligation separation agreements including tax matters agreement Letter Agreement impact global economic conditions company customers suppliers including foreign governments countries company operates fluctuations foreign exchange interest rates changes law concerning taxation income including current future tax reform including income earned outside United States actions tax authorities connection ongoing tax audits loss key employees inability identify recruit new employees outcome pending future litigation adequacy company cash flows operations meet ongoing cash obligations fund investment program factors identified elsewhere Annual Report Form 10-K including factors described Item 1A filings Securities Exchange Commission available company website Actual results may differ materially projected forward-looking statements The company undertake update forward-looking statements Item 7A Quantitative Qualitative